相似文献
1
Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa.
Bioorg Med Chem Lett. 2000 Feb 7;10(3):217-21. doi: 10.1016/s0960-894x(99)00673-3.
2
Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core.
Bioorg Med Chem Lett. 2001 Mar 12;11(5):641-5. doi: 10.1016/s0960-894x(01)00029-4.
3
Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors.
Bioorg Med Chem Lett. 2002 Jun 17;12(12):1657-61. doi: 10.1016/s0960-894x(02)00234-2.
4
Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
J Med Chem. 2004 Jul 29;47(16):4089-99. doi: 10.1021/jm0497491.
5
Evaluation of bisbenzamidines as inhibitors for matriptase-2.
Bioorg Med Chem Lett. 2016 Aug 1;26(15):3741-5. doi: 10.1016/j.bmcl.2016.05.071. Epub 2016 May 26.
6
Aminoisoquinolines: design and synthesis of an orally active benzamidine isostere for the inhibition of factor XA.
Bioorg Med Chem Lett. 1999 Sep 6;9(17):2539-44. doi: 10.1016/s0960-894x(99)00421-7.
7
Design of benzamidine-type inhibitors of factor Xa.
J Med Chem. 1998 Oct 22;41(22):4240-50. doi: 10.1021/jm980227t.
8
4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
Bioorg Med Chem Lett. 2002 Aug 5;12(15):2023-6. doi: 10.1016/s0960-894x(02)00312-8.
9
Nonbenzamidine compounds as selective factor Xa inhibitors.
Bioorg Med Chem Lett. 2000 Aug 7;10(15):1737-9. doi: 10.1016/s0960-894x(00)00316-4.
10
Design, synthesis, and SAR of amino acid derivatives as factor Xa inhibitors.
Bioorg Med Chem Lett. 2001 Nov 19;11(22):2947-50. doi: 10.1016/s0960-894x(01)00585-6.
Zotero 插件